Humana Q3 Net Income Plunges 59% Amid Rising Costs, Strategic Initiatives

Ticker: HUM · Form: 10-Q · Filed: 2025-11-05T00:00:00.000Z

Sentiment: mixed

Topics: Healthcare, Managed Care, Earnings Report, Operating Costs, Medicare Advantage, Profitability, Cash Flow

Related Tickers: HUM, UNH, CVS

TL;DR

**Humana's Q3 profit cratered, but the cash pile grew; watch if those 'value creation initiatives' actually pay off or just burn more cash.**

AI Summary

Humana Inc. reported a significant decrease in net income attributable to Humana for the three months ended September 30, 2025, falling to $195 million from $480 million in the prior-year period, a 59.4% decline. Diluted earnings per common share also dropped substantially to $1.62 from $3.98. Total revenues, however, increased by 11.1% to $32.649 billion for the three months ended September 30, 2025, up from $29.397 billion in 2024, driven by a rise in premiums to $30.711 billion from $27.951 billion. Operating expenses surged to $32.249 billion from $28.669 billion, primarily due to higher benefits costs of $27.991 billion and operating costs of $4.085 billion. The company incurred $267 million in charges for value creation initiatives, including severance and consulting, for the three months ended September 30, 2025, compared to $55 million in 2024. For the nine months ended September 30, 2025, net income attributable to Humana increased to $1.984 billion from $1.900 billion, while total revenues grew to $97.149 billion from $88.548 billion. Cash and cash equivalents significantly increased to $5.388 billion at September 30, 2025, from $2.221 billion at December 31, 2024. The company also recorded a $63 million loss on the sale of a business during the nine months ended September 30, 2025.

Why It Matters

Humana's sharp decline in Q3 net income, despite revenue growth, signals potential margin pressures and operational challenges that investors need to scrutinize. The substantial increase in operating costs, including $267 million for 'value creation initiatives,' suggests a significant restructuring effort that could impact employees through workforce optimization. For customers, these initiatives might lead to changes in service delivery or benefit structures as the company aims to fund growth in Medicare Advantage. In the broader market, this performance could reflect industry-wide pressures on healthcare providers, potentially affecting competitors like UnitedHealth Group or CVS Health's Aetna, and influencing investor sentiment towards the managed care sector.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant 59.4% drop in net income for the three months ended September 30, 2025, to $195 million, despite an 11.1% increase in total revenues. This indicates potential profitability challenges and increased operating expenses, including $267 million in charges for value creation initiatives, which could continue to impact short-term financial performance.

Analyst Insight

Investors should closely monitor Humana's upcoming earnings calls for detailed explanations of the 'value creation initiatives' and their expected return on investment. While the cash position improved significantly to $5.388 billion, the sharp decline in quarterly net income warrants caution; consider holding or reducing exposure until there's clearer evidence of these initiatives translating into sustainable profit growth.

Financial Highlights

revenue
$32.649B
net Income
$195M
eps
$1.62
cash Position
$5.388B
revenue Growth
+11.1%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenues$32.649B+11.1%

Key Numbers

Key Players & Entities

FAQ

What were Humana's total revenues for the three months ended September 30, 2025?

Humana's total revenues for the three months ended September 30, 2025, were $32.649 billion, an increase from $29.397 billion in the same period of 2024.

How did Humana's net income attributable to Humana change in Q3 2025 compared to Q3 2024?

Net income attributable to Humana decreased significantly to $195 million for the three months ended September 30, 2025, from $480 million in the prior-year period, representing a 59.4% decline.

What were the primary drivers of Humana's increased operating expenses in Q3 2025?

Operating expenses increased primarily due to higher benefits costs of $27.991 billion and operating costs of $4.085 billion. Additionally, the company incurred $267 million in charges for value creation initiatives.

What is Humana's strategic outlook regarding its Medicare Advantage business?

Humana is committed to driving additional value through cost saving and productivity initiatives to create capacity to fund growth and investment in its Medicare Advantage business and further expansion of its healthcare services capabilities.

What was Humana's cash and cash equivalents balance at September 30, 2025?

At September 30, 2025, Humana's cash and cash equivalents stood at $5.388 billion, a substantial increase from $2.221 billion at December 31, 2024.

Did Humana experience any significant losses from business divestitures in 2025?

Yes, Humana recorded a $63 million loss on the sale of a business for the nine months ended September 30, 2025.

What is the impact of 'Value Creation Initiatives' on Humana's financial statements?

The 'Value Creation Initiatives' resulted in charges of $267 million for the three months and $320 million for the nine months ended September 30, 2025, primarily from severance and external consulting, which are included in operating costs.

How does Humana's Q3 2025 diluted earnings per common share compare to the previous year?

Humana's diluted earnings per common share for Q3 2025 were $1.62, a decrease from $3.98 reported for the same period in 2024.

What new accounting pronouncements will affect Humana in future periods?

New accounting pronouncements include ASU 2023-09 (Income Taxes) effective for annual 2025, ASU 2024-03 (Expense Disaggregation Disclosures) effective for annual 2027, and ASU 2025-06 (Internal-Use Software) effective for interim 2028.

What is Humana's current number of common shares outstanding?

As of September 30, 2025, Humana had 120,273,068 shares of common stock, $0.16 2/3 par value, outstanding.

Risk Factors

Industry Context

The health insurance industry is highly competitive and subject to significant regulatory oversight. Companies like Humana operate in a complex environment with evolving healthcare policies and increasing demand for managed care services. Key trends include a shift towards value-based care, the growing importance of government programs (Medicare and Medicaid), and the need for technological innovation to manage costs and improve member experience.

Regulatory Implications

Humana operates in a heavily regulated sector, particularly with its significant presence in Medicare Advantage and Medicaid. Changes in government reimbursement rates, healthcare reform legislation, and compliance requirements pose ongoing risks. The company must navigate complex rules regarding coverage, benefits, and provider networks to maintain its market position and profitability.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Key Dates

Glossary

Value Creation Initiatives
Programs or actions undertaken by a company to improve its financial performance, efficiency, or strategic positioning. These can include restructuring, cost-cutting measures, or investments in new technologies. (Significant charges related to these initiatives impacted net income in Q3 2025.)
Diluted Earnings Per Common Share (EPS)
A measure of a company's profit allocated to each outstanding share of common stock, assuming that all convertible securities (like stock options and convertible bonds) were exercised or converted into common stock. (A key profitability metric that saw a substantial decrease in Q3 2025.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Humana Inc. experienced a significant 59.4% decline in net income attributable to Humana, falling to $195 million from $480 million, with diluted EPS dropping to $1.62 from $3.98. This was despite an 11.1% increase in total revenues to $32.649 billion, driven by higher premiums. The decline in profitability was exacerbated by a surge in operating expenses, particularly benefits costs, and a substantial increase in charges for value creation initiatives, which rose from $55 million to $267 million.

Filing Stats: 4,812 words · 19 min read · ~16 pages · Grade level 16.4 · Accepted 2025-11-05 12:07:03

Key Financial Figures

Filing Documents

: Financial Information

Part I: Financial Information

Financial Statements

Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) at September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements (Unaudited) 10

Management's Discussion and Analysis of Financial Condition and Results of Operations 34

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 34

Quantitative and Qualitative Disclosures about Market Risk 48

Item 3. Quantitative and Qualitative Disclosures about Market Risk 48

Controls and Procedures 48

Item 4. Controls and Procedures 48

: Other Information

Part II: Other Information

Legal Proceedings 49

Item 1. Legal Proceedings 49

Risk Factors 49

Item 1A. Risk Factors 49

Unregistered Sales of Equity Securities and Use of Proceeds 49

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49

Defaults Upon Senior Securities 49

Item 3. Defaults Upon Senior Securities 49

Mine Safety Disclosures 49

Item 4. Mine Safety Disclosures 49

Other Information 50

Item 5. Other Information 50

Exhibits 51

Item 6. Exhibits 51 Signatures 52 Certifications Humana Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 December 31, 2024 (in millions, except share amounts) ASSETS Current assets: Cash and cash equivalents $ 5,388 $ 2,221 Investment securities 16,736 18,214 Receivables, net of allowances of $ 124 in 2025 and $ 98 in 2024 2,684 2,704 Other current assets 7,944 6,676 Total current assets 32,752 29,815 Property and equipment, net 2,268 2,532 Long-term investment securities 440 421 Equity method investments 623 697 Goodwill 9,619 9,631 Other long-term assets 4,017 3,383 Total assets $ 49,719 $ 46,479 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Benefits payable $ 10,088 $ 10,440 Trade accounts payable and accrued expenses 5,519 5,259 Book overdraft 308 403 Unearned revenues 265 260 Short-term debt — 577 Total current liabilities 16,180 16,939 Long-term debt 12,607 11,144 Other long-term liabilities 2,350 1,951 Total liabilities 31,137 30,034 Commitments and Contingencies (Note 13) Stockholders' equity: Preferred stock, $ 1 par; 10,000,000 shares authorized; none issued — — Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,719,321 shares issued at September 30, 2025 and 198,718,810 shares issued at December 31, 2024 33 33 Capital in excess of par value 3,639 3,463 Retained earnings 29,980 28,317 Accumulated other comprehensive loss ( 666 ) ( 1,067 ) Treasury stock, at cost, 78,446,253 shares at September 30, 2025 and 78,077,195 shares at December 31, 2024 ( 14,464 ) ( 14,371 ) Total stockholders' equity 18,522 16,375 Noncontrolling interests 60 70 Total equity 18,582 16,445 Total liabilities and equity $ 49,719 $ 46,479 See accompanying notes to condensed consolidated financial statements. 3 Humana Inc. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 (in mill

View on Read The Filing